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Abstract: The presence of antigen-specific cellular immune responses may be an indicator of long-term asymptomatic 
HIV-1-disease. The detection of cellular immune responses to infection with different subtypes of HIV-1 may be ham-
pered by genetic differences of immunodominant antigens such as the capsid protein CAp24. In Nouna, Burkina Faso, 
HIV-1 circulating recombinant forms CRF02_AG and CRF06_cpx are the 2 major strains detectable in HIV-1-infected 
individuals, while subtype B strains prevail in Europe and North America. Amino acid sequences of CAp24 were assessed 
in blood samples from 10 HIV-1-infected patients in Nouna, Burkina Faso. Production of interferon-gamma (IFN-) in pe-
ripheral blood CD4
+ lymphocytes in response to recombinant HIV-1 proteins derived from clade B (including CAp24NL4-
3) was measured using a modified flow-cytometry-based whole blood short term activation assay (FASTimmune, BDBio-
sciences). IFN- production following stimulation with a whole length CAp24 protein derived from clade B (CAp24NL4-3) 
was additionally quantified in comparison to a CAp24 protein derived from CRF02_AG (CAp24BD6-15) in 16 HIV-1-
infected patients in Heidelberg, Germany. Amino acid sequence identity of CAp24 obtained from patients in Nouna 
ranged between 86 and 89% when compared to the clade B CAp24NL4-3 consensus sequence, between 90 and 95% when 
compared to the circulating recombinant form CRF06_CPX consensus sequence, and between 92 and 96% when com-
pared to the CAp24BD6-15 consensus sequence. Significant numbers of HIV-1-specific CD4
+ lymphocytes producing IFN- 
were detected in 4 of 10 HIV-1-infected patients. In 7 of 16 patients in Heidelberg, recombinant CAp24BD6-15 stimulated 
IFN--production in CD4
+ lymphocytes to a similar extent as the clade B-derived CAp24NL4-3. Thus, antigen-specific 
CD4
+ lymphocytes from both West African and European patients infected with different strains of HIV-1 show relevant 
cross-clade recognition of HIV-1 CAp24 in a flow-cytometry-based whole blood short term activation assay. 
INTRODUCTION 
  The presence of antigen-specific cellular immune re-
sponses may be an indicator of long-term asymptomatic 
HIV-1-disease [1]. However, the detection of cellular im-
mune responses to infection with different subtypes of HIV-
1 may be hampered by strain-specific differences of immu-
nodominant antigens especially in the CD4
+ subset. Norris et 
al. [2] observed that many of the naturally occurring HIV-1 
Gag epitope variants from clades A, B, C, D, and AE in-
duced less than 50% of the interferon- (IFN-)-response 
elicited by antigens based on the clade B consensus sequence 
in CD4
+ T cell clones from individuals with vigorous HIV-1-
specific T helper cell activity. On the other side, cross-
reactive cytotoxic T lymphocytes against antigens derived 
from clade A, B, C, or D were observed in patients infected 
with different HIV-1 subtypes in Uganda [3] and HIV-1 Gag 
peptide pools were able to elicit broad reactivity of CD8
+ T  
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cells across several subtypes of HIV-1 in chronically in-
fected patients in Malawi and the US [4] or the Netherlands 
[5]. 
MATERIALS AND METHODS 
  The Nouna Health Research Center (Centre de la Ré-
chèrche en Santé de Nouna, CRSN) and the Department of 
Virology of the University of Heidelberg, Germany, conduct 
a longitudinal trial of prevention of mother-to-child trans-
mission (PMTCT) of the human immunodeficiency virus 
type-1 (HIV-1) in Nouna, north-western Burkina Faso 
(West-Africa) [6]. The study was approved by the Institu-
tional Ethics Committees at the CRSN and the University of 
Heidelberg. Initial molecular analysis of blood samples from 
the research area identified the circulating recombinant 
forms CRF02_AG and CRF06_cpx as the predominant 
strains in HIV-1-infected individuals in Nouna [7]. 
Functional Analysis of HIV-1-Specific T Helper Cells 
  In a field-study in Nouna we screened 24 HIV-1-
seropositive (HIV-1
+) individuals (4 males and 20 females) 
for HIV-1-specific cytokine responses in peripheral blood Cross-Clade Recognition of HIV-1 CAp24 by CD4
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CD4
+ lymphocytes. Their median age was 33 years (range, 
18 to 62). Eight patients received antiretroviral therapy with 
a combination of Zidovudine, Lamivudine, and Nevirapine 
at the time of the study. Plasma viral load levels were deter-
mined in 20 patients and ranged from below detection 
threshold (<50 copies per ml) to 2.2*10
6 copies per ml (me-
dian 3.1*10
5 copies per ml). CD4 counts ranged from 87 to 
914 cells per l (median 390 cells per l). 
  All experiments in Nouna were performed on a FAC-
Scan flow cytometer equipped with CellQuest pro soft-
ware for data acquisition and analysis. Antigen-specific CD4
+ 
lymphocytes were quantified in freshly drawn heparinised 
peripheral venous blood by flow cytometry using FASTim-
mune reagents and protocols obtained from BD Biosciences 
(Erembodegem, Belgium, EU). T cells were stimulated for 9 
hours at 37°C using anti-CD28/anti-CD49d mAbs (1 g/ml) 
either alone or in combination with either Staphylococcal En-
terotoxin B (SEB, 5 g/ml; Sigma-Aldrich, München, Ger-
many), or a mixture of recombinant proteins derived from 
HIV-1 clade B, including the capsid protein CAp24NL4-3 (25 
g/ml as endotoxin-free solution in phosphate-buffered saline) 
[8], the HIV-1 regulator protein Tat ARP682.2 (8 g/ml), and 
the HIV-1 regulator Rev ARP663.2 (12.5 g/ml), the latter 
two obtained through NIBSC Centralised Facility for AIDS 
Reagents (EU Programme EVA AVIP, UK medical research 
council). During the last 4 hours of stimulation 10 g/ml Bre-
feldin A were added. 
 CD4
+ lymphocytes were identified by a combined 
SSC/FL-3 and FSC/SSC gating strategy and the proportion 
of CD69
+/INF-
+ double-positive cells was expressed as per-
centage of CD4
+ lymphocytes producing IFN-. The statisti-
cal significance of the difference between the percentage of 
IFN--producing CD4
+ lymphocytes after antigen stimulation 
and the corresponding unstimulated control was tested using 
the following power calculation: N = [2 * pav  * (1- pav) 
*10.5] / , where N is the number of events in each sample 
needed for a statistical significance of p<0.05 with a power 
of 90%, pav is the average proportion between the back-
ground and test samples, and  is the difference between 
these two proportions [9]. 
Amino Acid Sequence Analysis of CAp24 
  Four spots of EDTA buffy coat from each patient were 
dried at 37°C on IsoCode Card and DNA was extracted later 
according to the manufacturer’s recommendations (Schleic-her 
und Schuell, Dassel, Germany). DNA was used as template for 
nested PCR with the following combinations of oligonucleo-
tides (each 20 M; Invitrogen, Groningen, The Netherlands): 
forward primers CA1:1056-1088 (TCA AAG GAT AGG TAA 
AAG ACA CCA AGG AAG C), CA3:1109-1139 (TAC AAA 
ATA AGA GCA AAA AGA CAC AGC A), GAG1:789-815 
(TAT GGG TGC GAG AGC GTC GGT ATT AAG), and 
GAG3:836-875 (TGG GAA AAA TTC GGT TAA GGC C); 
reverse primers CA2:1169-1198 (TCT GGC TAG GTG TCC 
TTT GCC ACA GTT GAA), and CA4:1920-1952 (TTT TTG 
GCC CCT AAA ATT GCT TTT CTG CAT). A standard reac-
tion of 50 l contained 2 l template, 41 l dH20, 0.5 l Taq-
polymerase, 0.5 l forward primer, 0.5 l reverse primer, and 
0.5 l dNTP (dATP, dGTP, dCTP, dTTP). It was performed in 
40 cycles (30 sec at 94°C, 45 sec at 45°C, 1 min at 72°C) after 
initial denaturation for 2 min at 94°C and a final extension of 5 
min at 72°C. DNA fragments were cleaned with Nucleo Spin 
Extract kit (Macherey-Nagel, Düren, Germany) according to 
the manufacturer’s recommendations. 
  Sequencing was done by the primer walking method us-
ing the dye terminator cycle sequencing kit on a CEQ 2000 
capillary sequencer (Beckman Coulter, CA, USA). Contigs 
were assembled using the Contig Assembler of the Vector 
NTI Suite (Infomax, Oxford, UK). Sequences obtained were 
aligned with HIV-1 subtype reference sequences using the 
Seqpublisher HIV database (www.hiv-web.lanl.gov). 
Cross-Clade Recognition of CAp24 by T Helper Cells 
  We then purified both clade B-derived recombinant 
CAp24NL4-3 and CRF06_AG-derived CAp24BD6-15 [10] and 
compared the ability of the full length proteins to elicit HIV-
1-specific cytokine production at a concentration of 20 g/ml 
in peripheral blood CD4
+ lymphocytes of 16 HIV-infected 
patients in Heidelberg, Germany. All patients had CD4 
counts above 200 cells per l and plasma viral load levels of 
at least 2.0*10
3 copies per ml. Patients were infected either 
with clade B (n = 12), clade A (n = 2), clade C (n = 1), or 
CRF01_AE (n = 1). The experiments were performed on a 
FACScalibur flow cytometer with a slightly modified acti-
vation assay using CD154
+/IFN-
+ instead of CD69
+/INF-
+ 
double-positive CD4
+ cells for quantification of antigen-
specific cytokine responses [11]. 
RESULTS AND DISCUSSION 
  Flow-cytometry based functional screening revealed sig-
nificant IFN--responses in CD4
+ lymphocytes of 8 out of 24 
patients. Two of 7 responded to CAp24NL4-3 alone, 2 of 4 to 
CAp24NL4-3 and Tat, and 4 of 13 to CAp24NL4-3, Tat, and 
Rev. No correlation between the percentage of IFN--
producing HIV-1 specific CD4
+ lymphocytes and either the 
CD4
+ T cell counts or the plasma viral load levels was ob-
served. 
  It has been shown that the capsid protein CAp24 is 
among the most conserved immunodominant HIV proteins 
[12]. We therefore specifically assessed amino acid se-
quences of CAp24 in blood samples from 10 patients in 
Nouna (6 untreated, 4 receiving antiretroviral combination 
therapy) in order to calculate sequence identity between pa-
tient samples and consensus sequences of clade B and circu-
lating recombinant forms predominant in Nouna. 
  The resulting amino acid sequences are shown in Table 
1. Amino acid sequence identity of capsid proteins ranged 
between 86 and 89% when compared to the clade B 
CA_NL4-3 consensus sequence, between 90 and 95% when 
compared to the circulating recombinant form CRF06_cpx 
consensus sequence, and between 92 and 96% when com-
pared to the CRF02_AG consensus sequence previously de-
termined in our laboratory [7]. CD4
+  lymphocytes from 3 
untreated patients with CD4 counts above 200 cells per l 
and plasma viral load levels above 10
5 copies per ml had 
significant IFN--responses upon stimulation with the clade 6    The Open AIDS Journal, 2009, Volume 3  Böhler et al. 
B-based antigen preparations described above, but no spe-
cific amino acid positions that may determine HIV-1-
specific CD4
+ lymphocyte responses could be identified. 
  When the ability of the full length proteins CAp24NL4-3 and 
CAp24BD6-15 to elicit HIV-1-specific cytokine production in 
peripheral blood CD4
+ lymphocytes was directly compared in 
16 HIV-infected patients in Heidelberg, similar frequencies of 
HIV-1-specific CD4
+ lymphocytes were detected (Fig. 1). 
Both antigens gave concordant results in 13 patients (Pearson's 
r = 0.91; p<0.001) revealing significant IFN--production in 7 
patients (3 on antiretroviral combination therapy, 4 untreated) 
and no significant activation in 6 patients (5 on antiretroviral 
combination therapy, one untreated). Responders were in-
fected either with clade B (n = 5), clade A (n = 1), or 
Table 1.  Alignment of Amino Acid Sequences of CAp24 Retrieved from Plasma Viral RNA of 10 HIV-1-Infected Patients in Nouna 
Compared to the Clade B Laboratory Strain NL4-3 and the Circulating Recombinant Forms CRF06_cpx and CRF02_AG.  
 
CA_NL43    pivqnlqgqm vhqaisprtl nawvkvveek afspevipmf salsegatpq dlntmlntvg 
06_CPX     -----a---- ----m----- ------i-d- ---------- t--------- ---m---i-- 
02_AG      -----ak--- t--sm----- ------i--- g--------- ---------- ---m---i-- 
1*         -----a---- t---m----- ------i-d- ---------- t-------q- -------v-- 
2*         -----a---- ---------- ------i--- ---------- ---------- ---m---i-- 
3*         -----a---- ----m----- ------i--- s--------- ---------- ---m---i-- 
4          -----a---- ---s------ ------i--- ---------- t--------- ---m---i-- 
5          -----a--v- ---sl----- ---------r ---------- ---------- ---m---i-- 
6          -----a---- ----m----- ---------- ---------- t--------- ---m---i-- 
7          -----a---- ---------- ------i--- ---------- ---------- ---m---i-- 
8          -----a---- ---s------ ------i--- ---------- ---------- ---m---i-- 
9          -----a---- ---sm----- ------i--- ---------- ---------- ---m---i-- 
10         -v---a---- ----m----- ------i--- ---------- ---------- ---m---i--  60 
 
CA_NL43    ghqaamqmlk etineeaaew drlhpvhagp iapgqmrepr gsdiagttst lqeqigwmth 
06_CPX     ---------- d--------- --v------- -p---i---- ---------- ---------s 
02_AG      ---------- d--------- --v------- -p-------- ---------- ---------s 
1*         ---------- d--------- --i------- -p-------- ---------- -----a---g 
2*         ---------- d-------d- --v------- p--------- ---------- ---------g 
3*         ---------- d--------- --v------- v--------- ---------- ---------t 
4          ---------- d--------- --v------- np-------- ---------- ---------s 
5          ---------- d---d----- --t------- -p-------- ---------- ----v----s 
6          ---------- d--------- --t--aq--- yp---i-d-- ---------- -----a---s 
7          ---------- d-------d- --v------- p--------- ---------- ---------g 
8          ---------- d--------- --t------- -p-------- ---------- ---------s 
9          ---------- d--------- --m---q--- -p-------- ---------- ---------s 
10         ---------- d--------- --v------- vp-------- ---------- ---------s  120 
 
CA_NL43    nppipvgeiy krwiilglnk ivrmysptsi ldirqgpkep frdyvdrfyk tlraeqasqe 
06_CPX     ---------- ---------- -------vg- ---k------ --------f- -------t-- 
02_AG      ---------- ----v----- -------v-- ---------- --------f- -------t-- 
1*         ---v------ ---------- -------v-- ---------- --------f- i-----gt-- 
2*         ---------- ---------- -------v-- ---------- --------f- -------t-- 
3*         ---------- ---------- ---------- ---k------ --------f- -------t-- 
4          ---------- ----v----- -------v-- ---------- --------f- c------t-- 
5          ---v------ r--------- -------v-- ---k------ -k------f- ---------d 
6          ---------- ----v----- -------v-- ---------- --------f- -------t-d 
7          ---------- ---------- -------v-- ---------- -----h--f- -------t-- 
8          ---------- ----v----- -------v-- ---------- --------f- v------t-- 
9          ---------- ----v----- -------v-- ---------- --------f- -------t-- 
10         ---------- ---------- ---------- ---------- --------f- -------t--  180 
 
CA_NL43    vknwmtetll vqnanpdckt ilkalgpgat leemmtacqg vggpghkarv l 
06_CPX     ------d--- ---------- --r------- ---------- ---------- - 
02_AG      ---------- ---------s --r---t--- ---------- ---------- - 
1*         ---------- ---------s ---------- ---------- ----s----- - 
2*         ------d--- ---------- ---------- ---------- ---------- - 
3*         --g---d--- ---------- --r------- ---------- ----s----- - 
4          ---------- ---------s ------i--- ---------- ---------- - 
5          --g------- ---------- --r------- ---------- ---------i - 
6          ---------- ---------s --r------- ---------- ---------- - 
7          ------d--- ---------- ---------- ---------- ---------- - 
8          ---------- --------rs -------a-- ---------- ----s----- - 
9          ---------- ---s-----s ---------- ---------- ----s----- - 
10         ---------- ---------- ------s--- ---------- ----s----- - 
The asterisks (*) and lines in bold indicate patients with a significant IFN- response of CD4
+ lymphocytes after in vitro stimulation with recombinant CAp24NL4-3, dashes indicate (-) 
amino acid identity to the clade B laboratory strain NL4-3. Cross-Clade Recognition of HIV-1 CAp24 by CD4
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CRF01_AE (n = 1). Non-responders were infected with clade 
B (n = 5), or clade C (n = 1). Discordant results were seen in 3 
patients (one on antiretroviral combination therapy, 2 un-
treated, all infected with clade B). 
  Of interest, CAp24BD6-15 yielded slightly higher percent-
ages of cytokine-producing CD4
+ lymphocytes in nearly all 
patients studied (Fig. 1). Furthermore, at both study sites we 
did not observe unspecific stimulation of these cells in blood 
samples from healthy adult laboratory personnel by neither 
CAp24NL4-3 nor CAp24BD6-15. 
  We conclude from our data that there is significant cross-
clade recognition of the full-length proteins CAp24NL4-3 and 
CAp24BD6-15 by HIV-1 specific CD4
+ lymphocytes in patients 
in Europe and in Burkina Faso who are infected with different 
strains of HIV-1. The study showed that FACS-based testing of 
CD4
+ T cell function is feasible in a rural West African re-
search area – even if it may be difficult to reproduce the condi-
tions needed for high-throughput testing of HIV-1-specific 
CD4
+ T cells [1] outside a major urban research center. 
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Fig. (1). Correlation of antigen-specific CD4
+ lymphocyte responses elicited by HIV-1 clade B-derived CAp24NL4-3 (x-axis) and HIV-1 
CRF02.AG-derived CAp24BD6-15 (y-axis); Pearson‘s r = 0.91, p<0.001). The solid line indicates the identity line, broken lines indicate the 
threshold for statistically significant production of interferon- (IFN-). Black dots indicate patients with concordant, grey dots patients with 
discordant, and circles patients without significant production of IFN-. 
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